Randomised immunogenicity trial comparing 2019-2020 recombinant and egg-based influenza vaccines among frequently vaccinated healthcare personnel in Israel
Objectives: Trivalent inactivated influenza vaccine effectiveness was low in a prospective cohort of healthcare personnel (HCP) in Israel from 2016 to 2019. We conducted a randomised immunogenicity trial of quadrivalent recombinant influenza vaccine (RIV4) and standard-dose inactivated influenza vac...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S120197122400331X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846150171934588928 |
|---|---|
| author | Ashley L. Fowlkes Alon Peretz David Greenberg Avital Hirsch Emily T. Martin Min Z. Levine Laura Edwards Sarah Radke Adam S. Lauring Jill M. Ferdinands Chao Zhang Young M. Yoo Jacob Dreiher Gabriella Newes-Adeyi Eduardo Azziz-Baumgartner Alicia M. Fry Arnold S. Monto Ran Balicer Mark G. Thompson Mark A. Katz |
| author_facet | Ashley L. Fowlkes Alon Peretz David Greenberg Avital Hirsch Emily T. Martin Min Z. Levine Laura Edwards Sarah Radke Adam S. Lauring Jill M. Ferdinands Chao Zhang Young M. Yoo Jacob Dreiher Gabriella Newes-Adeyi Eduardo Azziz-Baumgartner Alicia M. Fry Arnold S. Monto Ran Balicer Mark G. Thompson Mark A. Katz |
| author_sort | Ashley L. Fowlkes |
| collection | DOAJ |
| description | Objectives: Trivalent inactivated influenza vaccine effectiveness was low in a prospective cohort of healthcare personnel (HCP) in Israel from 2016 to 2019. We conducted a randomised immunogenicity trial of quadrivalent recombinant influenza vaccine (RIV4) and standard-dose inactivated influenza vaccine (IIV4) among frequently and infrequently vaccinated previous cohort participants. Methods: From October 2019 to January 2020, we enrolled and randomly allocated HCP from two Israeli hospitals to receive IIV4 or RIV4. Hemagglutination inhibition (HAI) antibody titres against 2019-2020 vaccine reference influenza viruses were compared between vaccine groups using geometric mean titre (GMT) ratios from sera collected one-month post-vaccination and by frequency of vaccination in the past 5 years (>2 vs ≤2). Results: Among 415 HCP, the GMT ratio comparing RIV4 to IIV4 was 2.0 (95% confidence interval [CI] 1.7-2.7) for A(H1N1)pdm09, 1.6 (95% CI: 1.3-1.9) for A(H3N2), 1.8 (95% CI: 1.4-2.2) for B(Yamagata), and 1.1 (95% CI: 0.9-1.4) for B(Victoria). Similarly, RIV4 elicited higher HAI titres than IIV4 against all 2019-2020 vaccine reference viruses except B(Victoria) among infrequently and frequently vaccinated HCP (lower bound of GMT ratio 95% CIs ≥1.0). Conclusion: RIV4 had improved immunogenicity for influenza vaccine strains among both infrequent and frequent vaccinees compared to standard-dose IIV4. Clinical trials registration: NCT04523324 |
| format | Article |
| id | doaj-art-654557b4d71e4ee180f0f06513d0f979 |
| institution | Kabale University |
| issn | 1201-9712 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj-art-654557b4d71e4ee180f0f06513d0f9792024-11-29T06:23:09ZengElsevierInternational Journal of Infectious Diseases1201-97122024-12-01149107260Randomised immunogenicity trial comparing 2019-2020 recombinant and egg-based influenza vaccines among frequently vaccinated healthcare personnel in IsraelAshley L. Fowlkes0Alon Peretz1David Greenberg2Avital Hirsch3Emily T. Martin4Min Z. Levine5Laura Edwards6Sarah Radke7Adam S. Lauring8Jill M. Ferdinands9Chao Zhang10Young M. Yoo11Jacob Dreiher12Gabriella Newes-Adeyi13Eduardo Azziz-Baumgartner14Alicia M. Fry15Arnold S. Monto16Ran Balicer17Mark G. Thompson18Mark A. Katz19Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Corresponding author: Ashley Fowlkes, Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop A34, Atlanta, GA 30329, USA.Rabin Medical Center, Clalit Health Services, Beilinson Campus, Petah Tikva, IsraelSoroka University Medical Center, Clalit Health Services, Be'er Sheva, IsraelClalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, IsraelSchool of Public Health, University of Michigan, Ann Arbor, Michigan, USAInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USAAbt Associates, Inc., Atlanta, Georgia, USANational Institute of Health Innovation, University of Auckland, Auckland, New ZealandSchool of Public Health, University of Michigan, Ann Arbor, Michigan, USAInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USAInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USAInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USASoroka University Medical Center, Clalit Health Services, Be'er Sheva, IsraelAbt Associates, Inc., Atlanta, Georgia, USAInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USAInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USASchool of Public Health, University of Michigan, Ann Arbor, Michigan, USAClalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, IsraelInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USAClalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, IsraelObjectives: Trivalent inactivated influenza vaccine effectiveness was low in a prospective cohort of healthcare personnel (HCP) in Israel from 2016 to 2019. We conducted a randomised immunogenicity trial of quadrivalent recombinant influenza vaccine (RIV4) and standard-dose inactivated influenza vaccine (IIV4) among frequently and infrequently vaccinated previous cohort participants. Methods: From October 2019 to January 2020, we enrolled and randomly allocated HCP from two Israeli hospitals to receive IIV4 or RIV4. Hemagglutination inhibition (HAI) antibody titres against 2019-2020 vaccine reference influenza viruses were compared between vaccine groups using geometric mean titre (GMT) ratios from sera collected one-month post-vaccination and by frequency of vaccination in the past 5 years (>2 vs ≤2). Results: Among 415 HCP, the GMT ratio comparing RIV4 to IIV4 was 2.0 (95% confidence interval [CI] 1.7-2.7) for A(H1N1)pdm09, 1.6 (95% CI: 1.3-1.9) for A(H3N2), 1.8 (95% CI: 1.4-2.2) for B(Yamagata), and 1.1 (95% CI: 0.9-1.4) for B(Victoria). Similarly, RIV4 elicited higher HAI titres than IIV4 against all 2019-2020 vaccine reference viruses except B(Victoria) among infrequently and frequently vaccinated HCP (lower bound of GMT ratio 95% CIs ≥1.0). Conclusion: RIV4 had improved immunogenicity for influenza vaccine strains among both infrequent and frequent vaccinees compared to standard-dose IIV4. Clinical trials registration: NCT04523324http://www.sciencedirect.com/science/article/pii/S120197122400331XInfluenza vaccineRecombinantImmunogenicityHealthcare personnelFlublok |
| spellingShingle | Ashley L. Fowlkes Alon Peretz David Greenberg Avital Hirsch Emily T. Martin Min Z. Levine Laura Edwards Sarah Radke Adam S. Lauring Jill M. Ferdinands Chao Zhang Young M. Yoo Jacob Dreiher Gabriella Newes-Adeyi Eduardo Azziz-Baumgartner Alicia M. Fry Arnold S. Monto Ran Balicer Mark G. Thompson Mark A. Katz Randomised immunogenicity trial comparing 2019-2020 recombinant and egg-based influenza vaccines among frequently vaccinated healthcare personnel in Israel International Journal of Infectious Diseases Influenza vaccine Recombinant Immunogenicity Healthcare personnel Flublok |
| title | Randomised immunogenicity trial comparing 2019-2020 recombinant and egg-based influenza vaccines among frequently vaccinated healthcare personnel in Israel |
| title_full | Randomised immunogenicity trial comparing 2019-2020 recombinant and egg-based influenza vaccines among frequently vaccinated healthcare personnel in Israel |
| title_fullStr | Randomised immunogenicity trial comparing 2019-2020 recombinant and egg-based influenza vaccines among frequently vaccinated healthcare personnel in Israel |
| title_full_unstemmed | Randomised immunogenicity trial comparing 2019-2020 recombinant and egg-based influenza vaccines among frequently vaccinated healthcare personnel in Israel |
| title_short | Randomised immunogenicity trial comparing 2019-2020 recombinant and egg-based influenza vaccines among frequently vaccinated healthcare personnel in Israel |
| title_sort | randomised immunogenicity trial comparing 2019 2020 recombinant and egg based influenza vaccines among frequently vaccinated healthcare personnel in israel |
| topic | Influenza vaccine Recombinant Immunogenicity Healthcare personnel Flublok |
| url | http://www.sciencedirect.com/science/article/pii/S120197122400331X |
| work_keys_str_mv | AT ashleylfowlkes randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael AT alonperetz randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael AT davidgreenberg randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael AT avitalhirsch randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael AT emilytmartin randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael AT minzlevine randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael AT lauraedwards randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael AT sarahradke randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael AT adamslauring randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael AT jillmferdinands randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael AT chaozhang randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael AT youngmyoo randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael AT jacobdreiher randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael AT gabriellanewesadeyi randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael AT eduardoazzizbaumgartner randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael AT aliciamfry randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael AT arnoldsmonto randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael AT ranbalicer randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael AT markgthompson randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael AT markakatz randomisedimmunogenicitytrialcomparing20192020recombinantandeggbasedinfluenzavaccinesamongfrequentlyvaccinatedhealthcarepersonnelinisrael |